Zoster Vaccine Recombinant, Adjuvanted
Indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.
SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a sterile suspension for intramuscular injection. The vaccine is supplied as a vial of lyophilized recombinant varicella zoster virus surface glycoprotein E (gE) antigen component, which must be reconstituted at the time of use with the accompanying vial of AS01B adjuvant suspension component.
Key Regulatory Milestones
05/17/2019 - FDA approval date